Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement

Abstract

Deep venous thrombosis (DVT) and pulmonary embolism (PE) are serious and costly complications of total hip and knee replacement surgery. The risk of these complications is significantly reduced by prophylaxis. Low molecular weight heparins (LMWH) are being used for this indication with increased frequency. The objective of this study was to assess the cost implications of LMWH for the prevention of symptomatic DVT and PE complications following total hip and knee replacement surgery. The study design was cost analysis based on utilization and the costs of medical resources for prophylaxis and treatment of DVT/PE. A retrospective hospital data set was used to assess symptomatic DVT/PE complication rates and medical resource utilization in patients receiving warfarin, other, and no prophylaxis. The results of a clinical trial were used to estimate relative reductions in risk of symptomatic DVT/PE due to prophylaxis with LMWH. The 7721 total hip and knee replacement patients analyzed were admitted in 1992 in 57 acute-care non-federal hospitals. The measurements were of incremental costs or charges expected to be saved as a result of using LMWH prophylaxis instead of warfarin prophylaxis. Prophylaxis using LMWH rather than warfarin reduces the expected total costs (charges) of treatment by $50 ($193), not including the pharmaceutical costs associated with prophylaxis. The cost reduction in favor of LMWH was sensitive to several factors, including blood monitoring costs and DVT/PE complication rates. Where a reduction of one day in hospital stay could be realized from LMWH's early onset of action, the cost (charges) reduction increased to $226 ($624). In conclusion, LMWH has the potential to offer several short- and long-term cost advantages compared with warfarin, mostly due to lower test costs associated with prophylaxis and reduced complication rates.

Keywords

cost hip replacement knee replacement low molecular weight heparin prophylaxis warfarin

References

NIH consensus conference on prevention of venous thrombosis and pulmonary embolism. JAMA 1986; 256: 744-749.

Amstutz HC , Friscia DA , Dorey F , Carney BT. Warfarin prophylaxis to prevent mortality from pulmonary embolism after total hip replacement. J Bone Joint Surg Am 1989; 71A: 321-326.

Mohr DN , Silverstein MD , Ilstrup DM , Heit JA , Morrey BF. Venous thromboembolism associated with hip and knee arthroplasty: current prophylactic practices and outcomes. Mayo Clin Proc 1992; 67: 861-870.

Anderson FA , Wheeler HB , Goldberg RJ , Hosmer DW , Forcier A , Patwardhan NA. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991; 115: 591-595.

Grossman RS. Changing patterns of prophylaxis for deep venous thrombosis following elective hip replacement. Orthopedics 1993; 16: 19-22.

Anderson DR , O’Brien BJ , Levine MN , Roberts R , Wells PS , Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993; 119: 1105-1112.

Bergqvist D , Matzsch T , Jendteg S , Lindgren B , Persson U. The cost-effectiveness of prevention of post-operative thromboembolism. Acta Chir Scand Suppl 1990; 556: 36-41.

Hauch O , Khattar SC , Jorgensen LN. Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery. Semin Thromb Hemost 1991; 17 (suppl 3): 280-283.

Hull RD , Hirsh J , Sackett DL , Stoddart GL. Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high risk surgical patients. Can Med Assoc J 1982; 127: 990-995.

10.

Oster G , Tuden RL , Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA 1987; 257: 203-208.

11.

Paiement GD , Wessinger SJ , Harris WH. Cost-effectiveness of prophylaxis in total hip replacement. Am J Surg 1991; 161: 519-524.

12.

Menzin J , Richner R , Huse D , Colditz GA , Oster G. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. Ann Pharmacother 1994; 28: 271-275.

13.

Salzman EW , Davies GC. Prophylaxis of venous thromboembolism: analysis of cost effectiveness. Ann Surg 1980; 191: 207-218.

14.

Hyers TM , Hull RD , Weg J. Antithrombotic therapy for venous thromboembolic disease. Chest 1989; 95: 37S-37S.

15.

Drug facts and comparisons. St Louis, MO: Facts and Comparisons, Inc., 1994.

16.

RD Heparin Arthroplasty Group . RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am 1994; 76: 1174-1185.

17.

Leclerc JR , Geerts WH , Desjardins L et al. Prevention of deep vein thrombosis after major knee surgery - a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992; 67: 417-423.

18.

Levine MN , Hirsh J , Gent M et al. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114: 545-551.

19.

Turpie AG , Levine MN , Hirsh J et al. A randomized controlled trial of a low molecular weight heparin (enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929.

20.

Hoek JA , Nurmohamed MT , Hamelynck KJ et al. Prevention of deep vein thrombosis (DVT) following total hip replacement by a low molecular weight heparinoid (ORG 10172). Thromb Haemost 1992; 67: 28-32.

21.

Nurmohamed MT , Rosendaal FR , Buller HR et al. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta analysis. Lancet 1992; 340: 152-156.

22.

Hull RD , Raskob GE , Gent M et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA 1990; 263: 2313-2317.

23.

Imperiale TF , Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271: 1780-1785.

24.

Levine MN , Hirsh J. Hemorrhagic complications of anticoagulant therapy. Semin Thromb Hemost 1986; 12: 39-57.

25.

Redbook 1993. Montvale, NJ: Medical Economics Data, Inc., 1993.

26.

Hull R , Raskob G , Pineo G et al. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-1376.

27.

Brenkel IJ , Clancy MJ. Total hip replacement and antithrombotic prophylaxis. Br J Hosp Med 1989; 42: 282-284.

28.

Wittmann PH , Wittmann FW , Ring PA. Venous thromboembolic disease in uncemented total hip replacement surgery -a one-year follow-up of 490 patients. J R Soc Med 1991; 84: 536-539.

29.

Andersen M , Wille-Jorgensen P. Late complications of asymptomatic deep venous thrombosis. Eur J Surg 1991; 157: 527-530.

30.

Francis CW , Ricotta JJ , Evarts CM , Marder VJ. Long-term clinical observations and venous functional abnormalities after asymptomatic venous thrombosis following total hip or knee arthroplasty. Clin Orthop 1988; 232: 271-278.